GlycoEra AG, a biotechnology company pioneering best-in-class extracellular protein degraders for the treatment of autoimmune diseases, closed an oversubscribed $130 million Series B financing. The proceeds will be used to advance the Company’s lead protein degrader through clinical data in patients, bring a second program to the clinic and further develop its differentiated pipeline of precision extracellular degraders in immunology and additional indications..

GlycoEra AG是一家开发生物技术领域内领先的细胞外蛋白降解剂以治疗自身免疫性疾病的公司，完成了超额认购的1.3亿美元B轮融资。所得款项将用于推动公司的主要蛋白降解剂在患者中取得临床数据，将第二个项目引入临床，并进一步开发其在免疫学及其他适应症中差异化的精准细胞外降解剂管线。

GlycoEra’s

GlycoEra的

proprietary platform enables the development of best-in-class degraders that target a broad spectrum of extracellular proteins. GlycoEra’s degraders are bispecific molecules that leverage a naturally occurring process to degrade proteins, achieving exquisitely precise and sustained removal of disease-causing proteins with unprecedented speed and depth while avoiding systemic off-target effects.

专有平台能够开发出针对广泛细胞外蛋白的顶级降解剂。GlycoEra的降解剂是双特异性分子，利用自然发生的进程来降解蛋白质，实现对致病蛋白极其精确且持久的清除，速度和深度前所未有，同时避免了系统性的脱靶效应。

Unlike traditional approaches that require multi-step chemical synthesis, GlycoEra’s degraders are produced through a streamlined, one-step recombinant process, offering high efficiency, modularity, and scalability..

与需要多步化学合成的传统方法不同，GlycoEra 的降解剂通过简化的一步重组过程生产，具有高效、模块化和可扩展性。

GlycoEra’s lead program, GE8820, is designed to degrade pathogenic IgG4 autoantibodies with a speed, depth, and high level of selectivity not attainable with current modalities and without immunosuppression. Pathogenic IgG4 is a driver of a variety of autoimmune diseases such as pemphigus, muscle-specific kinase (MuSK) myasthenia gravis, primary membranous nephropathy, and autoimmune encephalitis.

GlycoEra的主导项目GE8820旨在以当前疗法无法达到的速度、深度和高选择性降解致病性IgG4自身抗体，且无需免疫抑制。致病性IgG4是多种自身免疫疾病的关键驱动因素，如天疱疮、肌肉特异性激酶（MuSK）重症肌无力、原发性膜性肾病和自身免疫性脑炎。

Preclinically, GE8820 has demonstrated deep and sustained IgG4 depletion in various models, giving it broad potential across numerous disease settings..

临床前，GE8820在多种模型中展现了深度且持续的IgG4耗竭，使其在众多疾病领域具有广泛的潜力。

First-in-human clinical trials later this year

今年晚些时候进行首次人体临床试验

“Our lead program, which has demonstrated deep and rapid IgG4 degradation preclinically, presents an opportunity to deliver transformative therapies to patients suffering from multiple autoimmune diseases. With this financing, we plan to initiate first-in-human clinical trials for our lead program later this year,” said Ganesh Kaundinya, Ph.D., President and Chief Executive Officer of GlycoEra.

“我们的主导项目在临床前研究中已展示了深度且快速的IgG4降解效果，为向多发自身免疫疾病的患者提供变革性治疗方案带来了机会。通过此次融资，我们计划在今年晚些时候启动主导项目的首次人体临床试验，”GlycoEra总裁兼首席执行官Ganesh Kaundinya博士表示。

“This financing is a strong validation of our science and platform, allowing us to accelerate our lead program into clinical development while advancing our robust pipeline of precision immunology medicines. We are grateful for the enthusiasm and support this prestigious group of investors has shown us, which reflect the progress of our differentiated protein degradation platform and our pipeline.”.

“这笔融资强烈验证了我们的科学和平台，使我们能够加速推进主导项目进入临床开发，同时推动我们强大的精准免疫药物管线。我们感谢这群杰出投资者对我们的热情和支持，这反映了我们差异化蛋白降解平台和研发管线的进展。”

The funding round was led by new investor

本轮融资由新投资者牵头。

Novo Holdings

诺和控股

, along with participation from additional new investors

，以及额外的新投资者的参与

Catalio Capital Management

卡塔利奥资本管理

,

，

LifeArc Ventures

LifeArc 风险投资

, and

，以及

QIA

启亚

, as well as existing investors

以及现有投资者

Sofinnova Partners

索菲诺瓦合伙公司

,

，

5AM Ventures

5AM创投

,

，

Roche Ventures

罗氏创投

, and

，以及

Bristol Myers Squibb

百时美施贵宝

. Additional new investors who joined the syndicate include

加入该财团的其他新投资者包括

Agent Capital

代理资本

,

，

MP Healthcare Venture Management

MP医疗保健风险投资管理

(a subsidiary of Mitsubishi Tanabe Pharma), and

（三菱田边制药的子公司），以及

Sixty Degree Capital

六十度首府

.

。

“GE8820’s ability to rapidly and deeply degrade pathogenic extracellular proteins with high specificity offers a potentially paradigm-shifting opportunity for the treatment of multiple autoimmune diseases,” said Max Klement, Partner at Novo Holdings. “With deep expertise in precision medicine, GlycoEra’s management team is well-positioned to redefine therapies in immunology, and we are proud to support their continued progress.”.

“GE8820能够快速且深度地降解病原性细胞外蛋白，并具有高度特异性，这为治疗多种自身免疫疾病提供了可能带来范式转变的机会，”Novo Holdings合伙人Max Klement表示。“凭借在精准医学领域的深厚专业知识，GlycoEra的管理团队有能力重新定义免疫学领域的治疗方法，我们很自豪能够支持他们的持续进展。”

“As a founding investor in GlycoEra, we have been consistently impressed with the team’s progress - advancing a truly unique platform and building a promising pipeline of protein degraders,” said Graziano Seghezzi, Managing Partner at Sofinnova Partners. “We’re glad to welcome new investors who share our commitment to advancing GlycoEra’s mission.

“作为GlycoEra的创始投资者，我们一直对团队的进展印象深刻——他们推进了一个真正独特的平台，并建立了一条充满前景的蛋白质降解剂管线，”Sofinnova Partners的管理合伙人格拉齐亚诺·塞格佐表示。“我们很高兴欢迎新投资者加入，他们与我们一样致力于推动GlycoEra的使命。”

This additional capital will help bring best-in-class degraders into the clinic and one step closer to patients living with autoimmune diseases.”.

这笔额外的资本将有助于将一流的降解剂引入临床，使自身免疫疾病患者更近一步。

GlycoEra is also announcing the additions of Max Klement, Matthew Hobson, Principal of Catalio Capital Management, and Sohaib Mir, Partner at LifeArc Ventures, to its board of directors.

GlycoEra还宣布，Max Klement、Catalio资本管理公司的负责人Matthew Hobson以及LifeArc Ventures的合伙人Sohaib Mir加入其董事会。

GlycoEra AG has been founded as a product development-focused spin-out of LimmaTech Biologics AG in 2020. The company is headquartered in Wädenswil, Switzerland with additional offices and labs in Newton, Massachusetts, USA.

GlycoEra AG 于2020年作为LimmaTech Biologics AG的产品开发分支成立。公司总部位于瑞士瓦滕维尔，并在美国马萨诸塞州牛顿设有额外的办公室和实验室。

(Press release / SK)

（新闻稿 / SK）

0

0

Comments

评论

Back to all news

返回所有新闻

Please

请

login

登录

or

或

sign up

注册

to comment.

评论。

Commenting guidelines

评论指南

Send

发送